GeneDx Holdings Corp.WGS
Price (close)
$88.48
Market cap
$2.6B
P/E
—
Revenue (TTM)
$454.4M
Net income
-$106.4M
Dividend yield
—
1-year total return
-21.7%
Net margin
-23.4%
Revenue growth
25.4%
Debt / equity
0.40x
What GeneDx Holdings Corp. does.
• “Legacy GeneDx” refer to GeneDx, LLC, a Delaware limited liability company, which we acquired on April 29, 2022 (the “Acquisition”);
• “Legacy Sema4” refer to Sema4 OpCo Inc., a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”);
• “Fabric Genomics” refer to Fabric Genomics, Inc., a Delaware corporation, which we acquired on May 5, 2025 (the “Merger”); and
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $179.3M | $212.2M | $234.7M | $202.6M | $305.4M | $427.5M |
| Net income | -$241.3M | -$245.4M | -$549.0M | -$175.8M | -$52.3M | -$21.0M |
| Free cash flow | -$117.2M | -$199.8M | -$326.3M | -$185.4M | -$34.0M | $14.3M |
More on WGS.
- GeneDx Holdings Corp. summary
- GeneDx Holdings Corp. financial statements
- GeneDx Holdings Corp. key metrics
- GeneDx Holdings Corp. health scores and style box
- GeneDx Holdings Corp. earnings
- GeneDx Holdings Corp. dividends
- GeneDx Holdings Corp. valuation
- GeneDx Holdings Corp. ownership and insiders
- GeneDx Holdings Corp. peers
Figures from GeneDx Holdings Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.